PURPOSE: To evaluate the clinical outcomes with linear accelerator-based multidose stereotactic radiosurgery (SRS) to large postoperative resection cavities in patients with large brain metastases. METHODS AND MATERIALS: Between March 2005 to May 2012, 101 patients with a single brain metastasis were treated with surgery and multidose SRS (9 Gy × 3) for large resection cavities (>3 cm). The target volume was the resection cavity with the inclusion of a 2-mm margin. The median cavity volume was 17.5 cm(3) (range, 12.6-35.7 cm(3)). The primary endpoint was local control. Secondary endpoints were survival and distant failure rates, cause of death, performance measurements, and toxicity of treatment. RESULTS: With a median follow-up of 16 months (range, 6-44 months), the 1-year and 2-year actuarial survival rates were 69% and 34%, respectively. The 1-year and 2-year local control rates were 93% and 84%, with respective incidences of new distant brain metastases of 50% and 66%. Local control was similar for radiosensitive (non-small cell lung cancer and breast cancer) and radioresistant (melanoma and renal cell cancer) brain metastases. On multivariate Cox analysis stable extracranial disease, breast cancer histology, and Karnofsky performance status >70 were associated with significant survival benefit. Brain radionecrosis occurred in 9 patients (9%), being symptomatic in 5 patients (5%). CONCLUSIONS: Adjuvant multidose SRS to resection cavity represents an effective treatment option that achieves excellent local control and defers the use of whole-brain radiation therapy in selected patients with large brain metastases.
PURPOSE: To evaluate the clinical outcomes with linear accelerator-based multidose stereotactic radiosurgery (SRS) to large postoperative resection cavities in patients with large brain metastases. METHODS AND MATERIALS: Between March 2005 to May 2012, 101 patients with a single brain metastasis were treated with surgery and multidose SRS (9 Gy × 3) for large resection cavities (>3 cm). The target volume was the resection cavity with the inclusion of a 2-mm margin. The median cavity volume was 17.5 cm(3) (range, 12.6-35.7 cm(3)). The primary endpoint was local control. Secondary endpoints were survival and distant failure rates, cause of death, performance measurements, and toxicity of treatment. RESULTS: With a median follow-up of 16 months (range, 6-44 months), the 1-year and 2-year actuarial survival rates were 69% and 34%, respectively. The 1-year and 2-year local control rates were 93% and 84%, with respective incidences of new distant brain metastases of 50% and 66%. Local control was similar for radiosensitive (non-small cell lung cancer and breast cancer) and radioresistant (melanoma and renal cell cancer) brain metastases. On multivariate Cox analysis stable extracranial disease, breast cancer histology, and Karnofsky performance status >70 were associated with significant survival benefit. Brain radionecrosis occurred in 9 patients (9%), being symptomatic in 5 patients (5%). CONCLUSIONS: Adjuvant multidose SRS to resection cavity represents an effective treatment option that achieves excellent local control and defers the use of whole-brain radiation therapy in selected patients with large brain metastases.
Authors: Ahmad Walid Ayas; Stefan Grau; Karolina Jablonska; Daniel Ruess; Maximilian Ruge; Simone Marnitz; Roland Goldbrunner; Martin Kocher Journal: Strahlenther Onkol Date: 2018-09-14 Impact factor: 3.621
Authors: Anthony L Asher; Mohammed Ali Alvi; Mohamad Bydon; Nader Pouratian; Ronald E Warnick; James McInerney; Inga S Grills; Jason Sheehan Journal: J Neurooncol Date: 2021-01-22 Impact factor: 4.130
Authors: Bree R Eaton; Michael J LaRiviere; Michael J La Riviere; Sungjin Kim; Roshan S Prabhu; Kirtesh Patel; Shravan Kandula; Nelson Oyesiku; Jeffrey Olson; Walter Curran; Hui-Kuo Shu; Ian Crocker Journal: J Neurooncol Date: 2015-04-11 Impact factor: 4.130
Authors: Tavish Nanda; Andrew Yaeh; Cheng-Chia Wu; Ashish Jani; Shumaila Saad; Yasir H Qureshi; Keith A Cauley; Jeraldine Lesser; Simon K Cheng; Steven R Isaacson; Michael B Sisti; Jeffrey N Bruce; Guy M McKhann; Sameer A Sheth; Andrew B Lassman; Tony J C Wang Journal: J Neurooncol Date: 2017-11-23 Impact factor: 4.130
Authors: Kamran A Ahmed; Jessica M Freilich; Yazan Abuodeh; Nicholas Figura; Neha Patel; Siriporn Sarangkasiri; Prakash Chinnaiyan; Hsiang-Hsuan Michael Yu; Arnold B Etame; Nikhil G Rao Journal: J Neurooncol Date: 2014-03-07 Impact factor: 4.130